Prognostic Significance of Vitamin D Receptor and Retinoid X Receptor Expression in Renal Cell Carcinoma

Journal of Urology

Volumn 178, Issue 4, 2007, Pages 1497-1503

  Obara, Wataru ^a   Konda, Ryuichiro ^a   Akasaka, Shuntaro ^a   Nakamura, Shinichi ^a   Sugawara, Akira ^b   Fujioka, Tomoaki ^a  

^a IWATE MEDICAL UNIVERSITY   (Japan)

^b TOHOKU UNIVERSITY HOSPITAL   (Japan)

Author keywords

calcitriol; carcinoma; kidney; prognosis; receptors; renal cell; retinoid X receptors

Indexed keywords

CALCITRIOL; COLECALCIFEROL; RETINOID X RECEPTOR; RETINOID X RECEPTOR ALPHA; RETINOID X RECEPTOR BETA; RETINOID X RECEPTOR GAMMA; VITAMIN D RECEPTOR;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; COMPLEX FORMATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; FEMALE; GENE EXPRESSION; HUMANS; KIDNEY; KIDNEY NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RECEPTORS, CALCITRIOL; RETINOID X RECEPTOR ALPHA; RETINOID X RECEPTOR BETA; RETINOID X RECEPTOR GAMMA; STATISTICS; SURVIVAL RATE;

EID: 34548403010     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2007.05.119     Document Type: Article

References (20)

1. Cohen H.T., and McGovern F.J. Renal-cell carcinoma. N Engl J Med 353 (2005) 2477
2. Motzer R.J., and Bukowski R.M. Targeted therapy for metastatic renal cell carcinoma. J Clin Oncol 24 (2006) 5601
3. Lamprecht S.A., and Lipkin M. Chemoprevention of colon cancer by calcium, vitamin D and folate: molecular mechanisms. Nat Rev Cancer 3 (2003) 601
4. Fujioka T., Hasegawa M., Ishikura K., Matsushita Y., Sato M., and Tanji S. Inhibition of tumor growth and angiogenesis by vitamin D3 agents in murine renal cell carcinoma. J Urol 160 (1998) 247
5. Barsony J., and Prufer K. Vitamin D receptor and retinoid X receptor interaction in motion. Vitamins Hormones 65 (2002) 345
6. Sugawara A., Sanno N., Takahashi N., Osamura R.Y., and Abe K. Retinoid X receptors in the kidney: their protein expression and functional significance. Endocrinology 138 (1997) 3175
7. Suzuki T., Moriya T., Sugawara A., Ariga N., Takabayashi H., and Sasano H. Retinoid receptors in human breast carcinoma: possible modulators of in situ estrogen metabolism. Breast Cancer Res Treat 65 (2001) 31
8. Konda R., Sato H., Hatafuku F., Nozawa T., Ioritani N., and Fujioka T. Expression of hepatocyte growth factor and its receptor C-met in acquired renal cystic disease associated with renal cell carcinoma. J Urol 171 (2004) 2166
9. Liu W., Tretiakova M., Kong J., Turkyilmaz M., Li Y.C., and Krausz T. Expression of vitamin D3 receptor in kidney tumors. Hum Pathol 37 (2006) 1268
10. Buentig N., Stoerkel S., Richter E., Dallmann I., Reitz M., and Atzpodien J. Predictive impact of retinoid X receptor-alpha-expression in renal-cell carcinoma. Cancer Biother Radiopharmacol 19 (2004) 331
11. Prufer K., Racz A., Lin G.C., and Barsony J. Dimerization with retinoid X receptors promotes nuclear localization and subnuclear targeting of vitamin D receptors. J Biol Chem 275 (2000) 41114
12. Lotan Y., Xu X.C., Shalev M., Lotan R., Williams R., Wheeler T.M., et al. Differential expression of nuclear retinoid receptors in normal and malignant prostates. J Clin Oncol 18 (2000) 116
13. Brabender J., Danenberg K.D., Metzger R., Schneider P.M., Lord R.V., Groshen S., et al. The role of retinoid X receptor messenger RNA expression in curatively resected non-small cell lung cancer. Clin Cancer Res 8 (2002) 438
14. Parker A.S., Cheville J.C., Lohse C.M., Igel T., Leibovich B.C., and Blute M.L. Loss of expression of von Hippel-Lindau tumor suppressor protein associated with improved survival in patients with early-stage clear cell renal cell carcinoma. Urology 65 (2005) 1090
15. Narayanan R., Sepulveda V.A., Falzon M., and Weigel N.L. The functional consequences of cross-talk between the vitamin D receptor and ERK signaling pathways are cell-specific. J Biol Chem 279 (2004) 47298
16. Zhuang S.H., Schwartz G.G., Cameron D., and Burnstein K.L. Vitamin D receptor content and transcriptional activity do not fully predict antiproliferative effects of vitamin D in human prostate cancer cell lines. Mol Cell Endocrinol 126 (1997) 83
17. Stio M., Celli A., and Treves C. Synergistic anti-proliferative effects of vitamin D derivatives and 9-cis retinoic acid in SH-SY5Y human neuroblastoma cells. J Steroid Biochem Mol Biol 77 (2001) 213
18. Gavrilov V., Steiner M., and Shany S. The combined treatment of 1,25-dihydroxyvitamin D3 and a non-steroid anti-inflammatory drug is highly effective in suppressing prostate cancer cell line (LNCaP) growth. Anticancer Res 25 (2005) 3425
19. Koshizuka K., Koike M., Kubota T., Said J., Binderup L., and Koeffler H.P. Novel vitamin D3 analog (CB1093) when combined with paclitaxel and cisplatin inhibit growth of MCF-7 human breast cancer cells in vivo. Int J Oncol 13 (1998) 421
20. Young M.R., and Lathers D.M. Combination docetaxel plus vitamin D(3) as an immune therapy in animals bearing squamous cell carcinomas. Otolaryngol Head Neck Surg 133 (2005) 611